On this video on OncoDaily TV, Dr. Sergey Badalyan sits down with Dr. Robert Lentz, Medical Director for Oncology at Natera, to debate the Natera’s newest gastrointestinal oncology analysis introduced at ASCO 2026 and ESMO GI 2026, the way forward for precision oncology and personalised most cancers care.
The dialogue explores how serial ctDNA testing with Signatera helps personalize remedy selections for sufferers with colorectal most cancers, by serving to oncologists higher perceive residual illness, remedy response, recurrence threat, and the potential profit of constant or altering remedy.
Dr. Lentz explains the most recent findings from the GALAXY examine, real-world immunotherapy analyses, and analysis in resected colorectal liver metastases, whereas discussing what these outcomes may imply for scientific observe and future potential trials.
